Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that CEO Greg Divis will participate in two upcoming investor conferences.

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that CEO Greg Divis will participate in two upcoming investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will feature a fireside chat starting on November 29, with an on-demand viewing available from November 22. The Evercore ISI 4th Annual HealthCONx Conference will include a fireside chat on December 1 at 2:00 p.m. ET. Webcasts and recordings of these events will be accessible on Avadel’s Investor Relations website for 90 days post-conference.

Argus Session date unavailable

+0.10% session move Open Argus

Details

News Market Reaction – AVDL

The recorded move for AVDL in the trading session of this news was +0.10%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:

• Piper Sandler 33^rd Annual Virtual Healthcare Conference: Participation starting on Monday, November 29 with a Fireside chat available for on-demand viewing starting today, Monday, November 22 at 10:00 a.m. ET.
• Evercore ISI 4^th Annual HealthCONx Conference: Fireside chat on Wednesday, December 1 at 2:00 p.m. E.T.

A webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com 
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com 
(408) 568-4292

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Avadel Pharmaceuticals participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference?

Avadel Pharmaceuticals will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference starting on November 29.

What time is the fireside chat for the Evercore ISI 4th Annual HealthCONx Conference?

The fireside chat for the Evercore ISI 4th Annual HealthCONx Conference is scheduled for December 1 at 2:00 p.m. ET.

Where can I find the webcasts of Avadel's investor conferences?

The webcasts and archived recordings of Avadel's investor conferences will be available on their Investor Relations website for 90 days following each conference.

What is the focus of Avadel Pharmaceuticals?

Avadel Pharmaceuticals focuses on transforming medicines to improve patients' lives, particularly through innovative drug delivery technologies.

What is the lead drug candidate of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' lead drug candidate is FT218, an investigational formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.